Condition
Relapsed/Refractory Hematological Malignancies
Total Trials
4
Recruiting
2
Active
2
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 4 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
4Total
P 1 (4)
Trial Status
Recruiting2
Not Yet Recruiting1
Unknown1
Clinical Trials (4)
Showing 4 of 4 trials
NCT07424833Phase 1RecruitingPrimary
A Study of APG-3288 in Relapsed/Refractory Blood Cancers
NCT07294300Phase 1Not Yet RecruitingPrimary
A Phase I Trial of QLS2313 Injection in Relapsed/Refractory Hematological Malignancies
NCT05528887Phase 1RecruitingPrimary
Study of CAR-T Cell Therapy in the Treatment of Relapsed/Refractory Hematological Malignancies
NCT04412577Phase 1UnknownPrimary
A Study of TQB3473 Tablets in Subjects With Relapsed or Refractory Hematological Malignancies
Showing all 4 trials